Management of the cardiac transplant recipient: Roles of the transplant cardiologist and primary care physician

American Journal of the Medical Sciences

Volumn 314, Issue 3, 1997, Pages 173-184

  Wagoner, Lynne E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Allograft coronary disease; Cardiac transplantation; Complications; Immunosuppression; Management

Indexed keywords

ACICLOVIR; ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATROPINE; AZATHIOPRINE; CIMETIDINE; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOBUTAMINE; ERYTHROMYCIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; ISOPRENALINE; KETOCONAZOLE; LYMPHOCYTE ANTIBODY; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORADRENALIN; OKT 3; PHENYTOIN; QUINIDINE; RANITIDINE; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; CLINICAL PRACTICE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEPHROTOXICITY; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE; SURVIVAL TIME; TREATMENT INDICATION;

EID: 0030829053     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199709000-00006     Document Type: Article

References (110)

1. Young JB, Winters WLJ, Bourge R, Uretsky BF. Task Force 4: Function of the heart transplant recipient. J Am Coll Cardiol. 1993;22:31-41.
2. Leachman RD, Cokkinos DV, Cabrera R, Leatherman LL, Rochelle DG. Response of the transplanted, denervated human heart to cardiovascular drugs. Am J Cardiol. 1971;27:272-6.
3. Yusuf S, Theodoropoulos S, Mathias CJ, Dhalla N, Wittes J, Mitchell A, et al. Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta adrenergic blockade. Circulation. 1987; 75:696-704.
4. Ellenbogen KA, Szentpetery S, Katz MR. Reversibility of prolonged chronotropic dysfunction with theophylline following orthotopic cardiac transplantation. Am Heart J. 1988;116:202-6.
5. Miyamoto Y, Curtiss EI, Kormos RL, Armitage JM, Hardesty RL, Griffith BP. Bradyarrhythmia after heart transplantation. Incidence, time course, and outcome. Circulation. 1990;82:IV-313-7.
6. Ellenbogen KA, Thames MD, DiMarco CJ, Sheehan H, Lerman BB. Electrophysiological effects of adenosine in the transplanted human heart: Evidence of super sensitivity. Circulation. 1990;81:821-8.
7. Goodman DJ, Rossen RM, Cannom DS, Rider RK, Harrison DC. Effect of digoxin on atrioventricular conduction: Studies in patients with and without cardiac autonomic innervation. Circulation. 1975;51:251-6.
8. Mason JW, Winkle RA, Rider AK, Stinson EB, Harrison DC. The electrophysiologic effects of quinidine in the transplanted human heart. J Clin Invest. 1977;59:481-9.
9. Bexton RS, Hellerstrand KJ, Cory-Pearce R, Spurrell RA, English TA, Camm AJ. The direct electrophysiologic effects of disopyramide phosphate in the transplanted human heart. Circulation. 1983;67:38-45.
10. Mason JW, Stinson EB, Harrison DC. Autonomic nervous system and arrhythmias: Studies in the transplanted denervated human heart. Cardiology. 1976;61:75-87.
11. Borow KM, Neumann A, Arensman FW, Yacoub MH. Cardiac and peripheral vascular responses to adrenoceptor stimulation and blockade after cardiac transplantation. J Am Coll Cardiol. 1989;14:1229-38.
12. Hosenpud JD, Novick RJ, Bennett LE, Keck BM, Fiol B, Daily OP. The registry of the International Society for Heart and Lung Transplantation: Thirteenth official report-1996. J Heart Lung Transplant. 1996;15:655-74.
13. O'Connell JB, Renlund DG. Diagnosis and treatment of cardiac allograft rejection. Cardiovasc Clin. 1990;20:147-62.
14. Sharples LD, Caine N, Mullins P, Scott JP, Solis E, English TA, et al. Risk factor analysis for the major hazards following heart transplantation - rejection, infection, and coronary occlusive disease. Transplantation. 1991; 52:244-52.
15. Caves PK, Stinson EB, Billingham ME, Rider AK, Shumway NE. Diagnosis of human cardiac allograft rejection by serial cardiac biopsy. J Thorac Cardiovasc Surg. 1973;66:461-6.
16. Billingham ME. Endomyocardial biopsy diagnosis of acute rejection in cardiac allografts. Prog Cardiovasc Dis. 1990;33:11-18.
17. Kobashigawa JA, Kirklin JK, Naftel DC, Bourge RC, Ventura HO, Mohanty PK, et al. Pre-transplant risk factors for acute rejection after cardiac transplantation: a multi-institutional study. J Heart Lung Transplant. 1993;12:355-66.
18. Winters GL, Costanzo-Nordin MR, O'Sullivan EJ, Pifarre R, Silver MA, Zucker MJ, et al. Predictors of late acute orthotopic heart transplant rejection. Circulation. 1989;80:III-106-10.
19. Wagoner LE, Taylor DO, Olsen SL, Ensley RD, Larsen CB, Hagan ME, et al. Physical assessment as a noninvasive test for detecting cardiac rejection (abstract). Proceedings of the Annual Meeting of the American Society of Transplant Physicians; Chicago IL: 1994.
20. Scott CD, Dark JH, McComb JM. Arrhythmias after cardiac transplantation. Am J Cardiol. 1992;70:1061-3.
21. Gill EA, Borrego C, Bray BE, Renlund DG, Hammond EH, Gilbert EM. Left ventricular mass increases during cardiac allograft vascular rejection. J Am Coll Cardiol. 1995;25:922-6.
22. Dodd DA, Brady LD, Carden KA, Frist WH, Boucek MM, Boucek RJJ. Pattern of echocardiographic abnormalities with acute cardiac allograft rejection in adults: Correlation with endomyocardial biopsy. J Heart Lung Transplant. 1993;12:1009-17.
23. Wagoner LE, Bray BE, Taylor DO, Renlund DG, Gilbert EM. Do echocardiographic parameters change over time in non-rejecting cardiac transplant recipients? (abstract). Proceedings of the Annual Meeting of the American Society of Transplant Physicians, Chicago, IL: 1994.
24. Valentine HA, Yeoh TK, Gibbons R, McCarthy P, Stinson EB, Billingham ME, et al. Sensitivity and specificity of diastolic indexes for rejection surveillance: Temporal correlation with endomyocardial biopsy. J Heart Lung Transplant. 1991;10:757-65.
25. Renlund DG, Gilbert EM, O'Connell JB, Gay WL Jr, Jones KW, Burton NA, et al. Age associated decline in cardiac allograft rejection. Am J Med. 1987;83:391-8.
26. Crandall BG, Renlund DG, O'Connell JB, Burton NA, Jones KW, Gay WA Jr, et al. Increased cardiac allograft rejection in female heart transplant recipients. J Heart Transplant. 1988;7:419-23.
27. Lavee J, Kormos RL, Duquesnoy RJ, Zerbe TR, Armitage JM, Vanek M, et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant. 1991; 10:921-30.
28. Kormos RL, Colson YL, Hardesty RL. Immunologic and blood group compatibility in cardiac transplantation. Transplant Proc. 1988;20:741-2.
29. Taylor DO, Bristow MR, O'Connell JB, Price GD, Hammond EH, Doty DB, et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant. 1996;15:1039-46.
30. Billingham ME, Cary NRB, Hammond ME, Kemnitz J, Marboe C, McCallister HA, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. J Heart Lung Transplant. 1990;9:587-93.
31. Lloveras JJ, Escourrou G, Delisle MG, Fournial B, Cerene A, Bassanetti I, et al. Evolution of untreated mild rejection in heart transplant recipients. J Heart Lung Transplant. 1992;11:751-6.
32. Laufer G, Laczkovics A, Wollenek G, Buxbaum P, Seitelberger R, Holzinger C, et al. The progression of mild acute cardiac rejection evaluated by risk factor analysis. Transplantation. 1991;51:184-9.
33. Costanzo-Nordin MR, Grusk DB, Silver MA, Sobotka PA, Winters GL, O'Connell JB, et al. Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation. 1988;78:III-47-57.
34. Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG. Mycophenolate mofetil (RS-61443): Preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant. 1994;13:571-82.
35. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation. Ann Thorac Surg. 1992;54:205-11.
36. Salter MM, Kirklin JK, Bourge RC, Naftel DC, White-Williams C, Tarkka M, et al. Total lymphoid irradiation in the treatment of early or recurrent heart rejection. J Heart Lung Transplant. 1992;11:902-12.
37. Rose EA, Barr ML, Xu H, Pepino P, Murphy MP, McGovern MA, et al. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant. 1992;11:746-50.
38. Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG. Task Force 5: Complications. J Am Coll Cardiol. 1993;22:41-54.
39. Miller LW. Long-term complications of cardiac transplantation. Prog Cardiovasc Dis. 1991;32:229-82.
40. Gentry LO. Cardiac transplantation and related infections. Sem Resp Inf. 1993;8:199-206.
41. Petri WJ. Infections in heart transplant recipients. Clin Infect Dis. 1994;18:141-6.
42. Bourge RC, Naftel DC, Nordin MC, Kirklin JK, Young JB, Kubo SH, et al. Pre-transplant risk factors for death after heart transplantation: A multi-institutional study. J Heart Lung Transplant. 1993;12:549-62.
43. Dummer SJ. Infectious complications of transplantation. Cardiovasc Clin. 1990;20:163-78.
44. Miller LW, Naftel DC, Bourge RC, Kirklin JK, Brozena SC. Infection following cardiac transplantation: A multi-institutional analysis (abstract). J Heart Lung Transplant. 1992;11:192.
45. Mason JW, Stinson EB, Hunt SA, Schroeder JS, Rider AK. Infections after cardiac transplantation: Relation to rejection therapy. Ann Intern Med. 1976;85:69-72.
46. Munoz P, Palomo J, Munoz R, Rodriguez-Creixems M, Pelaez T, Bouza E. Tuberculosis in heart transplant recipients. Clin Infect Dis. 1995;21:398-402.
47. Holliman RE, Johnson JD, Adams S, Pepper JR. Toxoplasmosis and heart transplantation. J Heart Transplant. 1991;10:608-10.
48. Olsen SL, Renlund DG, O'Connell JB, Taylor DO, Lassetter JE, Eastburn TE, et al. Prevention of pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation. 1993;56: 359-62.
49. Dummer JS, White LT, Ho M, Griffith BP, Hardesty RL, Bahnson HT. Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine. J Infect Dis. 1985;152:1182-91.
50. Merigan TC, Renlund DG, Keay S. A controlled trial of ganciclovir to prevent cytomgalovirus disease after heart transplantation. N Engl J Med. 1992;326:1182-6.
51. Keay S, Bisset J, Merigan TC. Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients. J Infect Dis. 1987;156:1016-21.
52. Hosenpud JD, Shipley GD, Wagner CR. Cardiac allograft vasculopathy: Current concepts, recent developments, and future directions. J Heart Lung Transplant. 1992;11:9-23.
53. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Valantine HA, Wiederhold V, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Circulation. 1989;80:III-100-5.
54. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Silverman JF, Wiederhold V, et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation. 1987;76:V-56-61.
55. Uretsky BF, Kormos RL, Zerbe TR, Lee A, Tokarczyk TR, Murali S, et al. Cardiac events after heart transplantation: Incidence and predictive value of coronary arteriography. J Heart Lung Transplant. 1992;11:545-51.
56. Wilson RF, Cristensen BV, Olivari MT, Simon A, White CW, Laxson DD. Evidence for structured reinnervation after orthotopic cardiac transplantation in humans. Circulation. 1991;83:1210-20.
57. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: Coronary arteriographic findings. J Am Coll Cardiol. 1988;12:34-40.
58. Ventura HO, Mehra MR, Smart FW, Stapleton DD. Cardiac allograft vasculopathy: Current concepts. Am Heart J. 1995;129:791-9.
59. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-7.
60. Sarris GE, Mitchell RS, Billingham ME, Glasson JR, Cahill PD, Miller CD. Inhibition of accelerated cardiac allograft arteriosclerosis by fish oil. J Thorac Cardiovasc Surg. 1989;97:841-55.
61. Schroeder JS, Gao SZ, Alderman EA, Hunt SA, Johnstone I, Boothroyd DB, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med. 1993;328:164-70.
62. Ensley RD, Hunt S, Taylor DO, Renlund DG, Menlove RL, Karwande SV, et al. Predictors of survival after repeat heart transplantation. J Heart Lung Transplant. 1992; 11:8142-58.
63. Halle AA, Wilson RF, Vetrovec GW, Group CTAS. Multicenter evaluation of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant. 1992;11:S138-41.
64. Penn I. Tumor incidence in human allograft recipients. Transplant Proc. 1977;11:1047-52.
65. Penn I. Cancer after cyclosporine therapy. Transplant Proc. 1988;20:276-9.
66. Armitage JM, Kormos RL, Griffith BP, Fricker EJ. Heart transplantation in patients with malignant disease. J Heart Transplant. 1990;627-29.
67. Lanza RP, Hingham MA; Cooper DKC, Lanza RP, eds. Heart Transplantation: Malignant neoplasm in the immunocompromised patient. Boston, MA: MTP Press; 1984:223-34.
68. Hanto DW, Sakamoto K, Purtilo DT, Simmons RL, Najarian JS. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Surgery. 1981;90:204-13.
69. Armitage JM, Kormos RL, Stuart RS, Fricker EJ, Griffith BP, Nalesnik M, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant. 1991;10:877-87.
70. Sullivan JL, Medveczky P, Forman SJ. Ebstein-Barr virus induced lymphoproliferation: Implications for antiviral chemotherapy. N Engl J Med. 1994;311:1163-7.
71. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression of the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med. 1990;323:1723-8.
72. Brumbaugh J, Baldwin JC, Stinson EB, Oyer PE, Jamieson SW, Bieber CP, et al. Quantitative analysis of immunosuppression in cyclosporine treated heart transplant patients with lymphoma. J Heart Transplant. 1985; 4:307-11.
73. Olivari MT, Kubo SH, Braunlin EA, Bolman RM, Ring WS. Five-year experience with triple-drug immunosuppressive therapy in cardiac transplantation. Circulation. 1990;82:IV-276-80.
74. Pham SM, Kormos RL, Kawai A, Murali S, Hattler BG, Demetris AJ, Griffith BP. Tacrolimus (FK 506) in clinical cardiac transplantation: A five-year experience. Transplant Proc. 1996;28:1002-4.
75. Renlund DG, O'Connell JB, Gilbert EM, Watson FS, Bristow MR. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J Heart Transplant. 1987;6:71-8.
76. Ventura HO, Lavie CJ, Messerli FH, Valentino V, Smart FW, Stapleton DD, et al. Cardiovascular adaptation to cyclosporine-induced hypertension. J Hum Hypertens. 1994;8:233-7.
77. Dart AM, Yeoh JK, Jennings GL, Cameron JD, Esmore DS. Circadian rhythms of heart rate and blood pressure after heart transplantation. J Heart Lung Transplant. 1992;11:784-92.
78. Lanuza DM, Grady K, Hetfleisch M, Johnson MR. Circadian rhythm changes in blood pressure and heart rate during the first year after heart transplantation. J Heart Lung Transplant. 1994;13:614-23.
79. Singer DR, Markandu ND, Buckley MG, Miller MA, Sagnella GA, Lachno DR, et al. Blood pressure and endocrine responses to changes in dietary sodium intake in cardiac transplant recipients. Implications for the control of sodium balance. Circulation. 1994;89:1153-9.
80. Meyer-Lehnert H, Schrier RW. Potential mechanisms of cyclosporine A induced vascular smooth muscle contraction. Hypertension. 1989;13:352-60.
81. Lustig S, Stern N, Eggena P, Tuck ML, Dee DB. Effect of cyclosporine on blood pressure and renin-aldosterone axis in rats. Am J Physiol. 1987;253:H1596-600.
82. Brozena SC, Johnson MR, Ventura H, Hobbs R, Miller L, Olivari MT, et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trial. J Am Coll Cardiol. 1996;27:1707-12.
83. Ventura HO, Milani RV, Lavie CJ, Smart FW, Stapleton DD, Toups TS, Price HL. Cyclosporine-induced hypertension. Efficacy of omega-3 fatty acids in patients after cardiac transplantation. Circulation. 1993;88:281-5.
84. Stamler JS, Vaughan DE, Rudd MA, Mudge GH, Kirshenbaum J, Young P, et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol. 1988;62:1268-72.
85. Kubo SH, Peters JR, Knutson KR, Hertz MI, Olivari MT, Bolman RM, et al. Factors influencing the development of hypercholesterolemia after heart transplantation. Am J Cardiol. 1992;70:520-6.
86. Becker DM, Chamberlain B, Swank R, Hegewald MG, Girardet R, Baughman KL, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med. 1988;85:632-8.
87. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM Jr, Young JB. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989;26:53-6.
88. Miller LW, Wolford T, McBride LR, Peigh P, Pennington DG. Successful withdrawal of steroids without use of induction therapy in cardiac transplantation. J Heart Lung Transplant. 1992;11:431-4.
89. Renlund DG, Bristow MR, Crandall BG, Burton NA, Doty DB, Karwande SV, et al. Hypercholesterolemia after heart transplantation: Amelioration by corticosteroid-free maintenance immunosuppression. J Heart Transplant. 1989;8:214-20.
90. Keogh A, Simons L, Spratt P, Esmore D, Chang V, Hickie J, Baron D. Hyperlipidemia after heart transplantation. J Heart Transplant. 1988;7:171-5.
91. Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation. 1990;82:IV-281-3.
92. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton RC, et al. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. J Amer Coll Card. 1992;19:1315-21.
93. Muchmore JS, Cooper DKC, Ye Y, Schlegel VT, Zuhdi N. Prevention of loss of vertebral bone density in heart transplant patients. J Heart Lung Transplant. 1992; 11:959-64.
94. Rich GM, Mudge GH, Laffel GL, LeBoff MS. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant. 1992;11:950-8.
95. Olivari MT, Antolick A, Kaye MP, Jamieson SW, Ring WS. Heart transplantation in elderly patients. J Heart Transplant. 1988;7:258-64.
96. Shane E, Rivas MD, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med. 1993;94:257-64.
97. Stein B, Takizawa M, Katz I, Joffe I, Berlin J, Fallon M, et al. Salmon calcitonin prevents cyclosporin-A induced high turnover bone loss. Endocrinology. 1991;129:92-8.
98. Merrell SW, Ames SA, Nelson EW. Major abdominal complications following cardiac transplantation. Arch Surg. 1989;124:889-94.
99. Spes CH, Angermann CE, Beyer RW, Schreiner J, Lehnert P, Kemkes BM, et al. Increased incidence for cholelithiasis in heart transplant recipients receiving cyclosporine therapy. J Heart Transplant. 1990;9:404-7.
100. Shade RR, Guglieimi A, Van Thiel DH. Cholestasis in heart transplant recipients treated with cyclosporine. Transplant Proc. 1983;15:2757-60.
101. Sekela ME, Hutchins DA, Young JB, Noon GP. Biliary surgery after cardiac transplantation. Arch Surg. 1991; 126:571-3.
102. Kawanishi H, Rudolph E, Bull FE. Azathioprine-induced acute pancreatitis. N Engl J Med. 1973;289:357.
103. Wagoner LE, Olsen SL, Bristow MR, O'Connell JB, Taylor DO, Lappe DL, et al. Cyclophosphamide as an alternative to azathioprine in cardiac transplant recipients with suspected azathioprine-induced hepatotoxicity. Transplantation. 1993;56:1415-8.
104. Hubbard S, Bivins BA, Lucas B, Litvak AS. Acute abdomen in the transplant patient. Am J Surg. 1980;46:116-20.
105. Wagoner LE, Taylor DO, Olsen SL, Price GS, Rasmussen LG, et al. Immunosuppressive therapy, management, and outcome of heart transplant recipients during pregnancy. Journal of Heart & Lung Transplantation. 1993: 13:993-1000.
106. Burrows L, Knight R, Thomas A, Panico M. Cyclosporine levels during pregnancy. Transplant Proc. 1994;26:2820-1.
107. Abukhalil IE, Govind A. Pregnancy in heart transplant recipients. Case report and review. Clin Exp Obstet Gynecol. 1995;22:111-4.
108. Catnach SM, McCarthy M, Jauniaux E, Fitt S, Tam KC, Nicolaides K, et al. Liver transplantation during pregnancy complicated by cytomegalovirus infection. Transplantation 1995;60:510-1.
109. Wagoner LE, Taylor DO, Price GS, Hagan ME, Holland C, Olsen SL, et al. Paternity by cardiac transplant recipients. Transplantation 1994;57:1337-40.
110. Crespigny P, d'Apice AJF. Parenthood after renal transplantation. Aust N Z J Med. 1986;16:245-6.